GlassScriptPhysician profile
David Ivan Jones
NPI 1427087741
$1,917.25
in general payments reported to CMS, 2019-2025
13 companies · $684 in 2025
The $684 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $212 · 2021: $332 · 2022: $121 · 2023: $189 · 2024: $147 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $520 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $519.74 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $710.41 | 2019-2021 | |
| Coopervision INC. | $549.64 | 2025 | Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $279.94 | 2021-2025 | Acuvue |
| Alcon Vision LLC | $177.59 | 2023-2025 | Precision 1, Total30, Precision7 |
| Bausch & Lomb Americas INC. | $53.64 | 2022-2023 | Biotrue |
| Livanova USA, INC. | $20.98 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Sun Pharmaceutical Industries INC. | $20.82 | 2022 | |
| Dompe US, INC. | $19.71 | 2025 | Oxervate |
| Abbvie INC. | $19.40 | 2024 | |
| Rxsight INC | $18.37 | 2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $15.59 | 2024 | Xdemvy |
| Teva Pharmaceuticals USA, INC. | $13.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.